¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"apolipoprotein"¿¡ ´ëÇÑ ¿µ¿µ ÀÇÇлçÀü ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
apolipoproteins b Structural proteins of chylomicrons, vldl, and ldl. They are important in the secretion and transport of these lipoproteins and represent the binding proteins for the ldl receptor pathway. Atherosclerotic patients show high levels of apo b in the blood while in the case of abetalipoproteinaemia they are not detectable in serum.
(12 Dec 1998)
apolipoproteins c Lipoproteins located on the surface of vldl. They are transferred to hdl throughout the catabolism of vldl and affect lipoprotein lipase activity. A genetic lack of apo c-II results in hyperglyceridemia and low levels of hdl. Another form of hyperglyceridemia with normal apo c-II levels is caused by a high concentration of apo c-III in vldl.
(12 Dec 1998)
apolipoproteins e Prominent protein constituents of plasma vldl, chylomicrons, and a subfraction of hdl as well as of remnant lipoproteins which are derived from the lipoprotein lipase-mediated intravascular catabolism of triglyceride-rich lipoproteins. Apolipoproteins e are recognised by the ldl receptor and apo e receptor. Any defect in the apo e metabolism leads to increased plasma apo e levels. A strong association has been found between high levels of apo e and type III hyperlipoproteinaemia.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á